Microsoft Excel LibreOffice Calc

Common-Size Statement of Financial Position, Liabilities and Stockholders' Equity

Difficulty: Beginner

Allergan PLC, Common-Size Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Accrued third-party rebates 1.52    1.24    0.94    2.29    2.71   
Contractual commitments, including amount due to Teva 0.60    0.21               
Accrued payroll and related benefits 0.54    0.42    0.30    0.74    1.06   
Accrued returns 0.32    0.23    0.21    0.23    0.45   
Interest payable 0.21    0.23    0.23    0.16    0.30   
Royalties payable 0.16    0.11    0.09    0.40    0.52   
Accrued pharmaceutical fees 0.16    0.17    0.12    0.25    0.07   
Accrued R&D expenditures 0.14    0.12    0.28    0.34    0.21   
Accrued severance, retention and other shutdown costs 0.11    0.07    0.08    0.24    0.39   
Litigation-related reserves and legal fees 0.07    0.08    0.16    0.79    1.17   
Accrued non-provision taxes 0.06    0.04    0.07    0.04    0.19   
Current portion of contingent consideration obligations 0.05    0.40    0.06    0.45    0.15   
Accrued selling and marketing expenditures 0.04    0.07    0.09    0.05    0.17   
Dividends payable 0.02    0.02    0.02           
Other accrued expenses 0.41    0.31    0.27    0.74    0.74   
Accrued expenses 4.41% 3.72% 2.93% 6.71% 8.14%
Accounts payable 0.27    0.17    0.27    1.23    2.17   
Accounts payable and accrued expenses 4.68% 3.89% 3.20% 7.94% 10.31%
Income taxes payable 0.06    0.04    0.04    0.10    0.43   
Current portion of long-term debt and capital leases 3.58    2.17    1.79    1.33    2.35   
Deferred revenue             0.05    0.17   
Current liabilities held for sale         1.10    0.05    1.09   
Deferred tax liabilities             0.09    0.15   
Current liabilities 8.32% 6.11% 6.13% 9.55% 14.50%
Long-term debt and capital leases, excluding current portion 21.84    23.24    29.66    28.26    37.48   
Acquisition related contingent consideration liabilities 0.36    0.51    0.58    0.30    0.80   
Long-term pension and post retirement liability 0.14    0.16    0.16    0.20    0.23   
Legacy Allergan deferred executive compensation 0.10    0.09    0.09           
Long-term severance and restructuring liabilities 0.04    0.02    0.03    0.01    0.12   
Deferred revenue 0.03    0.01    0.01    0.07    0.18   
Product warranties 0.02    0.02    0.02           
Long-term contractual obligations 0.04    0.02    0.02    0.06       
Litigation-related reserves             0.01    0.11   
Other long-term liabilities 0.02    0.02    0.02    0.07    0.18   
Other long-term liabilities 0.75% 0.84% 0.93% 0.71% 1.61%
Long-term liabilities held for sale         0.43           
Other taxes payable 1.33    0.69    0.59    1.70    0.82   
Deferred tax liabilities 5.37    10.05    5.88    5.83    3.62   
Non current liabilities 29.29% 34.82% 37.49% 36.50% 43.54%
Total liabilities 37.61% 40.92% 43.62% 46.06% 58.03%
Preferred shares, $0.0001 par value per share 4.17    3.82    3.63           
Ordinary shares; $0.0001 par value per share                    
Additional paid-in capital 45.64    41.83    50.43    55.20    35.26   
Retained earnings (accumulated deficit) 10.95    14.22    2.69    -0.38    6.30   
Accumulated other comprehensive income (loss) 1.62    -0.81    -0.36    -0.89    0.40   
Treasury stock, at cost                 -0.01   
Shareholders' equity 62.38% 59.07% 56.38% 53.93% 41.94%
Noncontrolling interest 0.01    0.01    -0.00    0.01    0.02   
Total equity 62.39% 59.08% 56.38% 53.94% 41.97%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00%